Focused On-demand Library for Interleukin-10 receptor subunit alpha

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q13651

UPID:

I10R1_HUMAN

Alternative names:

CDw210a; Interleukin-10 receptor subunit 1

Alternative UPACC:

Q13651; A8K6I0; B0YJ27

Background:

Interleukin-10 receptor subunit alpha (IL10RA), also known as CDw210a, plays a pivotal role in immune regulation. As a cell surface receptor for cytokine IL10, it initiates anti-inflammatory functions by limiting tissue disruption during inflammation. The binding of IL10 to IL10RA induces a conformational change, facilitating the assembly of a complex that activates kinases JAK1 and TYK2. These kinases phosphorylate IL10RA, leading to STAT3 activation and the expression of anti-inflammatory genes.

Therapeutic significance:

IL10RA's involvement in Inflammatory bowel disease 28, an autosomal recessive condition characterized by chronic inflammation of the gastrointestinal tract, underscores its therapeutic potential. Targeting IL10RA could offer new strategies for managing Crohn's disease and ulcerative colitis, conditions marked by excessive inflammation. Understanding IL10RA's role could open doors to innovative treatments that modulate the immune response in these debilitating diseases.